For example, at one day post MC infusion, gene expression analysis (Figures 6A–C) revealed a significant upregulation of genes associated with therapeutic benefits of trastuzumab [e.g. MATK (31)], tumor suppressors [RGS7 (32), MPPED2 (33)], and tumor cell apoptosis [IL-32 (34)]. This evidence concerns the gene MATK and neoplasm.